- Medicine (St Vincent's) - Research Publications
Medicine (St Vincent's) - Research Publications
Permanent URI for this collection
Search Results
Now showing
1 - 10 of 39
-
ItemNo Preview AvailableComparing abrocitinib and dupilumab in the treatment of atopic dermatitis: a plain language summaryBieber, T ; Simpson, EL ; Silverberg, J ; Thaci, D ; Paul, C ; Pink, AE ; Kataoka, Y ; Chu, C-Y ; DiBonaventura, M ; Rojo, R ; Antinew, J ; Ionita, I ; Sinclair, R ; Forman, S ; Zdybski, J ; Biswas, P ; Malhotra, B ; Zhang, F ; Valdez, H (FUTURE MEDICINE LTD, 2021-06-11)Atopic dermatitis (AD, also called atopic eczema) is a long-term skin disease that causes intensely itchy, red skin. Healthcare providers can prescribe medicated creams and ointments to reduce the signs and symptoms of AD. However, these treatments are not always enough to provide relief. A new medicine called abrocitinib, which is taken every day as a tablet, reduces part of the body's immune response that happens in AD. The clinical study described in this plain language summary, called JADE COMPARE, investigated how well and how safely 16 weeks of treatment with abrocitinib worked in adults with AD compared to placebo ('dummy treatment') and a medicine that is already approved for AD, called dupilumab. The study showed that abrocitinib was better than placebo in improving the signs and symptoms of AD after 16 weeks. In addition, patients who were taking abrocitinib 200 mg for 2 weeks experienced greater relief from itch than patients who were taking abrocitinib 100 mg, placebo, or dupilumab. More people who took abrocitinib 200 mg reported side effects than those taking abrocitinib 100 mg, placebo, or dupilumab, but most of these side effects were mild or moderate. ClinicalTrials.gov NCT number: NCT03720470.
-
ItemOnce-Daily Roflumilast Foam 0.3% Improves Severity and Burden of Itch in Patients With Scalp and Body Psoriasis in a Randomized, Double-blind, Vehicle-Controlled Phase 2b StudyMoore, A ; Alonso-Llamazares, J ; Bhatia, N ; Devani, A ; Bukhalo, M ; Draelos, Z ; Gooderham, M ; Kempers, S ; Kircik, L ; Papp, K ; Pariser, D ; Sankeva, M ; Sinclair, R ; Zirwas, M ; Feng, A ; Burnett, P ; Higham, R ; Berk, D (National Society for Cutaneous Medicine, 2021-11-05)N/A
-
ItemTrichodynia and telogen effluvium in COVID-19 patients: Results of an international expert opinion survey on diagnosis and management.Starace, M ; Iorizzo, M ; Sechi, A ; Alessandrini, AM ; Carpanese, M ; Bruni, F ; Vara, G ; Apalla, Z ; Asz-Sigall, D ; Barruscotti, S ; Camacho, F ; Doche, I ; Estrada, BD ; Dhurat, R ; Gavazzoni, MF ; Grimalt, R ; Harries, M ; Ioannidis, D ; McMichael, A ; Melo, DF ; Oliveira, R ; Ovcharenko, Y ; Pirmez, R ; Ramot, Y ; Rudnicka, L ; Shapiro, J ; Silyuk, T ; Sinclair, R ; Tosti, A ; Vano-Galvan, S ; Piraccini, BM (Elsevier BV, 2021-12)BACKGROUND: The cutaneous manifestations of COVID-19 may be useful disease markers and prognostic indicators. Recently, postinfectious telogen effluvium and trichodynia have also been reported. OBJECTIVE: To evaluate the presence of trichodynia and telogen effluvium in patients with COVID-19 and describe their characteristics in relation to the other signs and symptoms of the disease. METHODS: Patients with a history of COVID-19 presenting to the clinics of a group of hair experts because of telogen effluvium and/or scalp symptoms were questioned about their hair signs and symptoms in relation to the severity of COVID-19 and associated symptoms. RESULTS: Data from 128 patients were collected. Telogen effluvium was observed in 66.3% of the patients and trichodynia in 58.4%. Trichodynia was associated with telogen effluvium in 42.4% of the cases and anosmia and ageusia in 66.1% and 44.1% of the cases, respectively. In majority (62.5%) of the patients, the hair signs and symptoms started within the first month after COVID-19 diagnosis, and in 47.8% of the patients, these started after 12 weeks or more. LIMITATIONS: The recruitment of patients in specialized hair clinics, lack of a control group, and lack of recording of patient comorbidities. CONCLUSION: The severity of postviral telogen effluvium observed in patients with a history of COVID-19 infection may be influenced by COVID-19 severity. We identified early-onset (<4 weeks) and late-onset (>12 weeks) telogen effluvium.
-
ItemProxalutamide Reduces the Rate of Hospitalization for COVID-19 Male Outpatients: A Randomized Double-Blinded Placebo-Controlled Trial (Publication with Expression of Concern. See vol. 8, 2022) (Retracted article. See vol. 9, 2022)McCoy, J ; Goren, A ; Cadegiani, FA ; Vano-Galvan, S ; Kovacevic, M ; Situm, M ; Shapiro, J ; Sinclair, R ; Tosti, A ; Stanimirovic, A ; Fonseca, D ; Dorner, E ; Onety, DC ; Zimerman, RA ; Wambier, CG (FRONTIERS MEDIA SA, 2021-07-19)Antiandrogens have demonstrated a protective effect for COVOD-19 patients in observational and interventional studies. The goal of this study was to determine if proxalutamide, an androgen receptor antagonist, could be an effective treatment for men with COVID-19 in an outpatient setting. A randomized, double-blinded, placebo-controlled clinical trial was conducted at two outpatient centers (Brasilia, Brazil). Patients were recruited from October 21 to December 24, 2020 (clinicaltrials.gov number, NCT04446429). Male patients with confirmed COVID-19 but not requiring hospitalization (COVID-19 8-point ordinal scale <3) were administered proxalutamide 200 mg/day or placebo for up to 7 days. The primary endpoint was hospitalization rate at 30 days post-randomization. A total of 268 men were randomized in a 1:1 ratio. 134 patients receiving proxalutamide and 134 receiving placebo were included in the intention-to-treat analysis. The 30-day hospitalization rate was 2.2% in men taking proxalutamide compared to 26% in placebo, P < 0.001. The 30-day hospitalization risk ratio was 0.09; 95% confidence interval (CI) 0.03-0.27. Patients in the proxalutamide arm more frequently reported gastrointestinal adverse events, however, no patient discontinued treatment. In placebo group, 6 patients were lost during follow-up, and 2 patients died from acute respiratory distress syndrome. Here we demonstrate the hospitalization rate in proxalutamide treated men was reduced by 91% compared to usual care.
-
ItemNo Preview AvailableFrontal fibrosing alopeciaKerkemeyer, KLS ; Eisman, S ; Bhoyrul, B ; Pinczewski, J ; Sinclair, RD (Elsevier, 2021)Frontal fibrosing alopecia (FFA) is a patterned primary cicatricial alopecia that was first described in 1994. Once rare, the incidence of FFA has increased dramatically, representing the current most common cause of cicatricial alopecia worldwide. FFA typically begins in postmenopausal women with symmetrical, progressive recession of the frontotemporal hairline together with bilateral loss of the eyebrows. FFA has a distinctive clinical phenotype, which remains a challenge. The histology is identical to lichen planopilaris (LPP), but only a small number of patients have coincidental LPP, usually of the scalp. The vast majority of patients have no evidence of lichen planus elsewhere, and the symmetry and patterned nature of the hair loss are unusual for LPP. Familial cases of FFA are reported, and gene associations have been identified in population studies; however, the pathophysiology remains controversial. Without treatment, FFA is slowly progressive, and although many treatments have been prescribed, the response is often disappointing. We review the pathogenesis, epidemiology, clinical features, histology, and treatment of FFA.
-
ItemAndrogenetic alopecia may be associated with weaker COVID-19 T-cell immune response: An insight into a potential COVID-19 vaccine boosterGoren, A ; Cadegiani, FA ; Wambier, CG ; Vano-Galvan, S ; Tosti, A ; Shapiro, J ; Mesinkovska, NA ; Ramos, PM ; Sinclair, R ; Lupi, O ; Hercogova, J ; McCoy, J (CHURCHILL LIVINGSTONE, 2021-01-01)
-
ItemNo Preview AvailableTofacitinib for cutaneous and pulmonary sarcoidosis: A case seriesKerkemeyer, KL ; Meah, N ; Sinclair, RD (MOSBY-ELSEVIER, 2021-01-11)
-
ItemNo Preview AvailableThirty Years (and More) of Hair Research SocietiesWestgate, G ; Bergfeld, WF ; Ceh, V ; Hordinsky, M ; Sinclair, R ; Piraccini, BM ; Kang, H ; Ohyama, M (KARGER, 2021-02-01)The contributions of the core hair research societies and their members over the past 30 years have advanced the field of hair research and the understanding and treatment of hair disorders and normal hair growth.
-
ItemMinoxidil: What It Is and How It WorksSinclair, R (International Society of Hair Restoration Surgery, 2021-03)
-
ItemNo Preview AvailableEmerging Oral Treatments: Oral JAK Inhibitors for Alopecia AreataJohn, JM ; Sinclair, R (CRC Press, 2021-03-19)